Proteasome inhibitors as new anticancer drugs

Current Opinion in Oncology

Volumn 14, Issue 6, 2002, Pages 628-634

  Adams, Julian ^a  

^a MILLENNIUM PHARMACEUTICALS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BENZYLOXYCARBONYLISOLEUCYLGLUTAMYLALANYLLEUCYLLEUCINE; BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINE VINYLSULFONE; BORTEZOMIB; DOCETAXEL; EPONEMYCIN; EPOXOMICIN; GEMCITABINE; IRINOTECAN; LACTACYSTIN; PROTEASOME INHIBITOR; REGULATOR PROTEIN; TMC 95; UNCLASSIFIED DRUG; BORONIC ACID DERIVATIVE; CELL CYCLE PROTEIN; CYSTEINE PROTEINASE; MULTIENZYME COMPLEX; PROTEASOME; PROTEINASE INHIBITOR; PYRAZINE DERIVATIVE; TRANSCRIPTION FACTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANOREXIA; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER CELL; CANCER COMBINATION CHEMOTHERAPY; CELL CYCLE; CELL PROLIFERATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INHIBITION KINETICS; MONOTHERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; REVIEW; SOLID TUMOR; VOMITING; ANIMAL; CELL CULTURE; DISEASE MODEL; DRUG ANTAGONISM; DRUG EFFECT; RAT;

ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BORONIC ACIDS; CELL CYCLE PROTEINS; CLINICAL TRIALS; CYSTEINE ENDOPEPTIDASES; DISEASE MODELS, ANIMAL; HUMANS; MULTIENZYME COMPLEXES; PROTEASE INHIBITORS; PROTEASOME ENDOPEPTIDASE COMPLEX; PYRAZINES; RATS; TRANSCRIPTION FACTORS; TUMOR CELLS, CULTURED;

EID: 0036855056     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001622-200211000-00007     Document Type: Review

References (60)

1. Rock KL, Gramm C, Rothstein L, et al.: Inhibitors of the proteasome block the degradation of most cell proteins and the generation of peptides presented on MHC class I molecules. Cell 1994, 78:761-771.
2. Zwickl P, Voges D, Baumeister W: The proteasome: A macromolecular assembly designed for controlled proteolysis. Philos Trans R Soc Lond B Biol Sci 1999, 354:1501-1511.
3. Kumatori A, Tanaka K, Inamura N, et al.: Abnormally high expression of proteasomes in human leukemic cells. Proc Natl Acad Sci U S A 1990, 87:7071-7075.
4. Shah SA, Potter MW, Callery MP: Ubiquitin proteasome pathway: Implications and advances in cancer therapy. Surg Oncol 2001, 10:43-52. A concise review of the advances in proteasome inhibition to mid-2001. Includes details of specific proteasome targets and the role of the proteasome in apoptosis and chemoresistance.
5. MacLaren AP, Chapman RS, Wyllie AH, et al.: p53-dependent apoptosis induced by proteasome inhibition in mammary epithelial cells. Cell Death Differ 2001, 8:210-218.
6. Wilkinson KD: Ubiquitin-dependent signaling: The role of ubiquitination in the response of cells to their environment. J Nutr 1999, 129:1933-1936.
7. Pickart CM: Mechanisms underlying ubiquitination. Annu Rev Biochem 2001, 70:503-533. A comprehensive review of ubiquitination, focusing on the enzymes involved in protein targeting.
8. Groll M, Koguchi Y, Huber R, et al.: Crystal structure of the 20 S proteasome:TMC-95A complex: A non-covalent proteasome inhibitor. J Mol Biol 2001, 311:543-548.
9. Nussbaum AK, Dick TP, Keilholz W, et al.: Cleavage motifs of the yeast 20S proteasome beta subunits deduced from digests of enolase 1. Proc Natl Acad Sci U S A 1998, 95:12504-12509.
10. Adams J, Behnke M, Chen S, et al.: Potent and selective inhibitors of the proteasome: Dipeptidyl boronic acids. Bioorg Med Chem Lett 1998, 8:333-338.
11. Kisselev AF, Goldberg AL: Proteasome inhibitors: From research tools to drug candidates. Chem Biol 2001, 8:739-758.
12. Dick LR, Cruikshank AA, Grenier L, et al.: Mechanistic studies on the inactivation of the proteasome by lactacystin: A central role for clasto-lactacystin beta-lactone. J Biol Chem 1996, 271:7273-7276.
13. Fenteany G, Standaert RF, Lane WS, et al.: Inhibition of proteasome activities and subunit-specific amino-terminal threonine modification by lactacystin. Science 1995, 268:726-731.
14. Tomoda H, Omura S: Lactacystin, a proteasome inhibitor: Discovery and its application in cell biology. Yakugaku Zasshi 2000, 120:935-949.
15. Kozlowski L, Stoklosa T, Omura S, et al.: Lactacystin inhibits cathepsin A activity in melanoma cell lines. Tumor Biol 2001, 22:211-215.
16. Bogyo M, McMaster JS, Gaczynska M, et al.: Covalent modification of the active site threonine of proteasomal beta subunits and the Escherichia coli homolog HslV by a new class of inhibitors. Proc Natl Acad Sci U S A 1997, 94:6629-6634.
17. Meng L, Mohan R, Kwok BH, et al.: Epoxomicin, a potent and selective proteasome inhibitor, exhibits in vivo antiinflammatory activity. Proc Natl Acad Sci USA 1999, 96:10403-10408.
18. Meng L, Kwok BH, Sin N, et al.: Eponemycin exerts its antitumor effect through the inhibition of proteasome function. Cancer Res 1999, 59:2798-2801.
19. Ma MH, Parker KM, Manyak S, et al.: Proteasome inhibitor PS-341 markedly enhanced sensitivity of multiple myeloma cells to chemotherapeutic agents and overcomes chemoresistance through inhibition of the NF-κB pathway [abstract]. Blood 2001, 98:473a.
20. Soligo D, Servida F, Delia D, et al.: The apoptogenic response of human myeloid leukaemia cell lines and of normal and malignant haematopoietic pro-genitor cells to the proteasome inhibitor PSI. Br J Haematol 2001, 113:126-135.
21. Drexler HC: Activation of the cell death program by inhibition of proteasome function. Proc Natl Acad Sci U S A 1997, 94:855-860.
22. Drexler HC, Risau W, Konerding MA: Inhibition of proteasome function induces programmed cell death in proliferating endothelial cells. FASEB J 2000, 14:65-77.
23. Bold RJ, Virudachalam S, McConkey DJ: Chemosensitization of pancreatic cancer by inhibition of the 26S proteasome. J Surg Res 2001, 100:11-17.
24. Oyaizu H, Adachi Y, Okumura T, et al.: Proteasome inhibitor 1 enhances pa-clitaxel-induced apoptosis in human lung adenocarcinoma cell line. Oncol Rep 2001, 8:825-829.
25. Li QQ, Yunmbam MK, Zhong X, et al.: Lactacystin enhances cisplatin sensitivity in resistant human ovarian cancer cell lines via inhibition of DNA repair and ERCC-1 expression. Cell Mol Biol (Noisy-le-Grand) [Serial Online] 2001, 47:OL61-OL72.
26. Cusack JC Jr, Liu R, Houston M, et al.: Enhanced chemosensitivity to CPT-11 with proteasome inhibitor PS-341: Implications for systemic nuclear factor-kappaB inhibition. Cancer Res 2001, 61:3535-3540. A good example of proteasome inhibition enhancing the chemosensitivity of cancer cells both in vitro and in vivo. Discusses the role of NFκB in chemoresistance.
27. Pervan M, Pajonk F, Sunday JR, et al.: Molecular pathways that modify tumor radiation response. Am J Clin Oncol 2001, 24:481-485.
28. Russo SM, Tepper JE, Baldwin AS Jr, et al.: Enhancement of radiosensitivity by proteasome inhibition: Implications for a role of NF-kappaB. Int J Radiat Oncol Biol Phys 2001, 50:183-193.
29. Hideshima T, Richardson P, Chauhan D, et al.: The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res 2001, 61:3071-3076.
30. Kurland JF, Meyn RE: Protease inhibitors restore radiation-induced apoptosis to Bcl-2- expressing lymphoma cells. Int J Cancer 2001, 96:327-333.
31. Shah SA, Potter MW, McDade TP, et al.: 26S proteasome inhibition induces apoptosis and limits growth of human pancreatic cancer. J Cell Biochem 2001, 82:110-122. A detailed study demonstrating the direct apoptotic effect of PS-341 in vitro and the chemosensitizing effect of PS-341 in vivo. This work is of particular interest given the aggressive nature of pancreatic cancer and the lack of effective therapy to date.
32. Fan XM, Wong BC, Wang WP, et al.: Inhibition of proteasome function induced apoptosis in gastric cancer. Int J Cancer 2001, 93:481-488.
33. Adams J, Palombella VJ, Sausville EA, et al.: Proteasome inhibitors: A novel class of potent and effective antitumor agents. Cancer Res 1999, 59:2615-2622.
34. Naujokat C, Sezer O, Zinke H, et al.: Proteasome inhibitors induced caspase-dependent apoptosis and accumulation of p21WAF1/Cip1 in human immature leukemic cells. Eur J Haematol 2000, 65:221-236.
35. Liotta LA, Liu ET: Essentials of molecular biology: Basic principles. In Cancer: Principles and Practice of Oncology, 6th Ed. Edited by DeVita VT, Hellman S, Rosenberg SA. Philadelphia: Lippincott Williams & Wilkins; 2001.
36. An WG, Hwang SG, Trepel JB, et al.: Protease inhibitor-induced apoptosis: Accumulation of wt p53, p21WAF1/CIP1, and induction of apoptosis are independent markers of proteasome inhibition. Leukemia 2000, 14:1276-1283.
37. Jeremias I, Kupatt C, Baumann B, et al.: Inhibition of nuclear factor kappaB activation attenuates apoptosis resistance in lymphoid cells. Blood 1998, 91:4624-4631.
38. Wu Y, Luo H, Kanaan N, Wu J: The proteasome controls the expression of a proliferation-associated nuclear antigen Ki-67. J Cell Biochem 2000, 76:596-604.
39. Sunwoo JB, Chen Z, Dong G, et al.: Novel proteasome inhibitor PS-341 inhibits activation of nuclear factor-kappa B, cell survival, tumor growth, and angiogenesis in squamous cell carcinoma. Clin Cancer Res 2001, 7:1419-1428. A study demonstrating that PS-341 as a single agent induces tumor regression and reduces blood vessel density in vivo.
40. Chen C, Edelstein LC, Gelinas C: The Rel/NF-kappaB family directly activates expression of the apoptosis inhibitor Bcl-x(L). Mol Cell Biol 2000, 20:2687-2695.
41. Wang CY, Mayo MW, Korneluk RG, et al.: NF-kappaB antiapoptosis: Induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation. Science 1998, 281:1680-1683.
42. Wang CY, Guttridge DC, Mayo MW, et al.: NF-kappaB induces expression of the Bcl-2 homologue A1/Bfl-1 to preferentially suppress chemotherapy-induced apoptosis. Mol Cell Biol 1999, 19:5923-5929.
43. Zong WX, Edelstein LC, Chen C, et al.: The prosurvival Bcl-2 homolog Bfl-1/A1 is a direct transcriptional target of NF-kappaB that blocks TNFalpha-induced apoptosis. Genes Dev 1999, 13:382-387.
44. Tricot G: New insights into role of microenvironment in multiple myeloma. Lancet 2000, 355:248-250.
45. Kordes U, Krappmann D, Heissmeyer V, et al.: Transcription factor NF-kappaB is constitutively activated in acure lymphoblastic leukemia cells. Leukemia 2000, 14:399-402.
46. Patel NM, Nozaki S, Shortle NH, et al.: Paclitaxel sensitivity of breast cancer cells with constitutively active NF-kappaB is enhanced by IkappaBalpha super-repressor and parthenolide. Oncogene 2000, 19:4159-4169.
47. Um JH, Kang CD, Lee BG, et al.: Increased and correlated nuclear factor-kappa B and Ku autoantigen activities are associated with development of multidrug resistance. Oncogene 2001, 20:6048-6056.
48. Cusack JC, Liu R, Baldwin AS: NF-kappa B and chemoresistance: Potentiation of cancer drugs via inhibition of NF-kappa B. Drug Resist Updat 1999, 2:271-273.
49. Almond JB, Snowden RT, Hunter A, et al.: Proteasome inhibitor-induced apoptosis of B-chronic lymphocytic leukaemia cells involves cytochrome c release and caspase activation, accompanied by formation of an approximately 700 kDa Apaf-1 containing apoptosome complex. Leukemia 2001, 15: 1388-1397.
50. Wagenknecht B, Hermisson M, Groscurth P, et al.: Proteasome inhibitor-induced apoptosis of glioma cells involves the processing of multiple caspases and cytochrome c release. J Neurochem 2000, 75:2288-2297.
51. Teicher BA, Ara G, Herbst R, et al.: The proteasome inhibitor PS-341 in cancer therapy. Clin Cancer Res 1999, 5:2638-2645.
52. Frankel A, Man S, Elliott P, et al.: Lack of multicellular drug resistance observed in human ovarian and prostate carcinoma treated with the proteasome inhibitor PS-341. Clin Cancer Res 2000, 6:3719-3728.
53. Kumeda SI, Deguchi A, Toi M, et al.: Induction of G1 arrest and selective growth inhibition by lactacystin in human umbilical vein endothelial cells. Anticancer Res 1999, 19:3961-3968.
54. LeBlanc R, Catley L, Hideshima T, et al.: Proteasome inhibitor PS-341 inhibits human multiple myeloma cell growth in a murine model [abstract]. Blood 2001, 98:774a.
55. Pham L, Tamayo A, Lo P, et al.: Antitumor activity of the proteasome inhibitor PS-341 in mantle cell lymphoma B cells [abstract]. Blood 2001, 98:465a.
56. Steiner P, Neumeier H, Lightcap ES, et al.: Generation of PS-341-adapted human multiple myeloma cells as experimental tools for analysis of proteasome function in cancer [abstract]. Blood 2001, 98:310a.
57. Richardson PG, Berenson J, Irwin D, et al.: Phase II study of PS-341, a novel proteasome inhibitor, alone or in combination with dexamethasone, in patients with multiple myeloma who have relapsed following front-line therapy and are refractory to their most recent therapy [abstract]. Blood 2001, 98:774a.
58. Ryan DP, Eder JP, Winkelmann J, et al.: Pharmacokinetic and pharmacodynamic phase I study of PS-341 and gemcitabine in patients with advanced solid tumors. Proc Am Soc Clin Oncol 2002, 21:95a.
59. Clark JW, Ryan D, Dees C, et al.: Phase I dose-escalation study of the proteasome inhibitor, PS-341, plus irinotecan in patients with advanced solid tumors. Proc Am Soc Clin Oncol 2002, 21:93a.
60. Palombella VJ, Conner EM, Fuseler JW, et al.: Role of the proteasome and NF-kappaB in streptococcal cell wall-induced polyarthritis. Proc Natl Acad Sci U S A 1998, 95:15671-15676.